title: Coping with the isotretinoin registry.
abstract: The isotretinoin registry has arrived. It has a lofty goal of preventing all isotretinoin pregnancies. How we got to this point and what the registry means to prescribers and patients have many dermatologists confused and concerned. Will it be burdensome, will it preclude the use in most offices of this most important drug? Will it breed a new group of "isotretinologists" who are willing to take on the challenge? This article endeavors to answer these questions and to put most concerns at rest. The new system seems ultimately to have few changes compared to the risk management program we are already (technically) following. The difference is that compliance with all the rules will be monitored and mandatory. The system seems user friendly, is accessible to the computer-savvy as well as those of us still addicted to telephone, and may well turn out to be much fuss made over minimal hassle. What is clear is that this is likely our last chance to save this wonderful drug from oblivion. It is time for dermatologists to step to the plate and do what is in the best interest of their patients.
authors.affiliation: Department of Dermatology, State University of New York, Brooklyn, New York, USA. hbaldwin@downstate.edu
authors.forename: Hilary E
authors.initials: HE
authors.lastname: Baldwin
mesh_terms: D000014:Abnormalities, Drug-Induced / Q000453:epidemiology / Q000517:prevention & control*; D000152:Acne Vulgaris / Q000188:drug therapy*; D005260:Female; D006801:Humans; D015474:Isotretinoin / Q000633:toxicity*; D007641:Keratolytic Agents / Q000633:toxicity*; D011247:Pregnancy; D012042:Registries; D012308:Risk Management; D014481:United States / Q000453:epidemiology
chemical_list: D007641:Keratolytic Agents; D015474:Isotretinoin